SEMrush

Breaking News

Home / abpnews home / Indanlatestnews / Bharat Biotech's Covaxin Safe, Phase 3 Trial Data Shows 77.8% Efficacy Against Symptomatic Covid: Lancet

Bharat Biotech's Covaxin Safe, Phase 3 Trial Data Shows 77.8% Efficacy Against Symptomatic Covid: Lancet

نوفمبر 11, 2021 ,
Bharat Biotech's Covaxin Safe, Phase 3 Trial Data Shows 77.8% Efficacy Against Symptomatic Covid: Lancet

ليست هناك تعليقات

الاشتراك في: تعليقات الرسالة ( Atom )